Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations

被引:54
作者
Krutilkova, V
Trkova, M
Fleitz, J
Gregor, V
Novotna, K
Krepelova, A
Sumerauer, D
Kodet, R
Siruckova, S
Plevova, P
Bendova, S
Hedvicakova, P
Foreman, NK
Sedlacek, Z
机构
[1] Charles Univ Prague, Inst Biol & Med Genet, Sch Med 2, Prague 15006 5, Czech Republic
[2] Univ Hosp Motol, Prague 15006 5, Czech Republic
[3] Univ Colorado, Hlth Sci Ctr, Dept Pediat Hematol Oncol, Denver, CO USA
[4] Univ Colorado, Hlth Sci Ctr, BMT, Denver, CO USA
[5] Childrens Hosp, Denver, CO 80218 USA
[6] Thomayer Univ Hosp, Dept Med Genet, Prague, Czech Republic
[7] Inst Postgrad Educ, Dept Med Genet, Prague, Czech Republic
[8] Charles Univ Prague, Dept Paediat Haematol & Oncol, Sch Med 2, Prague 15006 5, Czech Republic
[9] Charles Univ Prague, Dept Pathol & Mol Med, Sch Med 2, Prague 15006 5, Czech Republic
[10] Univ Ostrava, Univ Hosp Ostrava, Dept Med Genet, Ostrava, Czech Republic
关键词
choroid plexus carcinoma; childhood brain tumours; TP53 germline mutations; Li-Fraumeni syndrome; genetic counselling; Turner syndrome;
D O I
10.1016/j.ejca.2005.01.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We present five families of paediatric patients suffering from choroid plexus carcinoma in which we found germline TP53 mutations. Only one of the families conformed to the criteria of Li-Fraumeni syndrome and only three (including the Li-Fraumeni syndrome family) met the Chompret criteria for germline TP53 mutation testing. In the remaining two families no family history of cancer was identified and/or the parents of the patient were shown not to carry the mutation. Our results give further support to the notion that the occurrence of this rare paediatric tumour, especially in combination with a positive family history of cancer, but possibly also without any family history, may be an indicator of a germline TP53 mutation. The identification of this genetic defect has important consequences for cancer prevention and treatment in affected families. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1597 / 1603
页数:7
相关论文
共 32 条
[1]  
BIRCH JM, 1994, CANCER RES, V54, P1298
[2]   Relative frequency and morphology of cancers in carriers of germline TP53 mutations [J].
Birch, JM ;
Alston, RD ;
McNally, RJQ ;
Evans, DGR ;
Kelsey, AM ;
Harris, M ;
Eden, OB ;
Varley, JM .
ONCOGENE, 2001, 20 (34) :4621-4628
[3]  
Chompret A, 2000, BRIT J CANCER, V82, P1932
[4]   Sensitivity and predictive value of criteria for p53 germline mutation screening [J].
Chompret, A ;
Abel, A ;
Stoppa-Lyonnet, D ;
Brugières, L ;
Pagès, S ;
Feunteun, J ;
Bonaïti-Pellié, C .
JOURNAL OF MEDICAL GENETICS, 2001, 38 (01) :43-47
[5]  
FREBOURG T, 1995, AM J HUM GENET, V56, P608
[6]  
GARBER JE, 1990, CANCER-AM CANCER SOC, V66, P2658, DOI 10.1002/1097-0142(19901215)66:12<2658::AID-CNCR2820661232>3.0.CO
[7]  
2-C
[8]   Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2 [J].
Huusko, P ;
Castrén, K ;
Launonen, V ;
Soini, Y ;
Pääkkönen, K ;
Leisti, J ;
Vähäkangas, K ;
Winqvist, R .
CANCER GENETICS AND CYTOGENETICS, 1999, 112 (01) :9-14
[9]   II. Perinatal brain tumors: A review of 250 cases [J].
Isaacs, H .
PEDIATRIC NEUROLOGY, 2002, 27 (05) :333-342
[10]  
JOLLY KW, 1994, ONCOGENE, V9, P97